Summary & Overview
HCPCS Level II J9058: Bendamustine Hydrochloride Injection, 1 mg
HCPCS Level II code J9058 denotes the injectable oncology agent bendamustine hydrochloride (apotex), billed per 1 mg. This code is nationally relevant because bendamustine is an established chemotherapy agent for certain hematologic malignancies; accurate coding affects drug cost reporting, reimbursement, and inventory management across outpatient and office infusion settings. Key national payers considered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise briefing on the clinical context for J9058, typical sites of service where the product is administered, and which major payers are covered in the analysis. The publication summarizes billing and coding considerations, common modifiers used with injectable chemotherapy (listed separately), and national payer policies and benchmarks where available. It also outlines common administrative issues such as unit-based billing for milligram-dosed agents, potential documentation elements required by payers, and where to look for payer-specific prior authorization or coverage guidance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9058 represents an injection of bendamustine hydrochloride (apotex), 1 mg. This billing code is used for administration of the listed oncology cytotoxic agent in measured milligram units.
-
Service type: Intravenous chemotherapy drug administration billed per milligram
-
Typical site of service: Hospital outpatient department, physician office infusion suite, or oncology clinic infusion center
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with relapsed indolent non-Hodgkin lymphoma presents to the outpatient oncology infusion center for systemic chemotherapy. The oncology team prescribes bendamustine hydrochloride administered intravenously per weight-based dosing. The clinical workflow: pre-visit nurse screening for recent labs and performance status; verification of chemotherapy order in the electronic medical record and pharmacy preparation of J9058 (bendamustine hydrochloride) in the appropriate concentration and bag; patient check-in and vitals collection; review of informed consent and allergy status; premedication as indicated (antiemetic and antihistamine or steroid) documented; IV access secured and sites evaluated; administration of bendamustine with continuous monitoring for infusion reactions and hematologic toxicity; post-infusion observation, documentation of total drug mg administered (units of J9058 billed per 1 mg), and discharge instructions including follow-up labs and oncology clinic appointment. Typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic. The typical patient scenario includes hematologic malignancy management, often combined with other systemic agents or supportive care medications, and may require modifier use to indicate unusual circumstances (for example, 22 for increased procedural services or 52 for reduced services) depending on complexity and billing rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|